Cefuroxime Axetil Dispersible Tablets

This product is a second-generation cephalosporin antibiotic. After oral absorption through the gastrointestinal tract, it is rapidly hydrolyzed into cefuroxime under the action of esterase to exert its antibacterial effect. Its activity against Gram-positive cocci is similar to or slightly worse than that of the first-generation cephalosporins, but it is quite stable against β-lactamase produced by Staphylococci and Gram-negative bacilli. Except for methicillin-resistant Staphylococci, Enterococci and Listeria, other positive cocci (including anaerobic cocci) are sensitive to this product. The antibacterial activity of this product against Staphylococcus aureus is worse than that of cefazolin. 1-2 mg/L of this product can inhibit all Staphylococcus aureus that are sensitive and resistant to penicillin, respectively. It has strong antibacterial activity against Haemophilus influenzae, Escherichia coli, Proteus mirabilis, etc. are sensitive to this product; indole-positive Proteus, Citrobacter and Acinetobacter are poorly sensitive to this product, most Serratia are resistant, Pseudomonas aeruginosa, Campylobacter and Bacteroides fragilis are resistant to this product. The mechanism of action of this product is to inhibit the synthesis of bacterial cell walls.

Cefuroxime axetil. Chemical name: 6R, 7R)-7-[2-furanyl(methoxyimino)acetylamino]-3-carbamoyloxymethyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 1-acetoxyethyl ester. Molecular weight: C20H22N4O10S

This product is a film-coated tablet, which appears off-white after removing the coating.

This product is suitable for acute pharyngitis or tonsillitis in adults, acute otitis media, maxillary sinusitis, acute exacerbation of chronic bronchitis, acute bronchitis, simple urinary tract infection, skin and soft tissue infection, and uncomplicated gonorrhea Neisseria urethritis and cervicitis caused by sensitive strains of Enterobacteriaceae such as hemolytic streptococci, Staphylococcus aureus (except methicillin-resistant strains), Haemophilus influenzae, Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis. It is also suitable for pharyngitis or tonsillitis, acute otitis media, and impetigo in children.

1. Adults generally take 0.5g a day; patients with lower respiratory tract infection: 1g a day; 2. Patients with simple lower urinary tract infection: 0.25g a day. Take it in 2 divided doses. 3. The single-dose therapy dose for simple gonococcal urethritis is 1g. 4. Children aged 5 to 12 years with acute pharyngitis or acute tonsillitis: take 20mg/kg a day according to body weight, divided into 2 doses, not exceeding 0.5g a day; 5. Acute otitis media, impetigo: take 30mg/kg a day according to body weight, divided into 2 doses, not exceeding 1g a day.

1. Common gastrointestinal reactions include diarrhea, nausea and vomiting. 2. Rare allergic reactions include rash and drug fever. 3. Occasionally, pseudomembranous colitis, eosinophilia, increased blood bilirubin, decreased hemoglobin, changes in renal function, positive Coombs test and transient increase in liver enzymes are seen.

It is contraindicated in patients who are allergic to cephalosporin antibiotics.

Precautions for children: Children under 5 years old are prohibited from using this product. They should take cefuroxime axetil suspension. Precautions for pregnancy and lactation: Use with caution in pregnant women. Since cefuroxime is excreted in human milk, it should be used with caution in lactating women. If it is necessary to use it, breastfeeding should be temporarily stopped. Precautions for the elderly: Elderly patients do not need to adjust the dosage based on age factors.

1. Furosemide, ethacrynic acid, bumetanide and other strong diuretics, carmustine, streptozocin and other anti-tumor drugs and aminoglycoside antibiotics and other nephrotoxic drugs combined with this product may increase nephrotoxicity. 2. Clavulanic acid can enhance the antibacterial activity of this product against certain Gram-negative bacteria that are resistant to this product due to the production of β-lactamase. 3. This product combined with probenecid can increase the area under the drug-time curve (AUC value) of this product by about 50%. 4. This product combined with antacids can reduce the absorption of this product.

Sealed and stored in a cool place.

0.25g (calculated as C16H16N4O8S)

24 months

Shandong Zibo Xinda Pharmaceutical Co., Ltd.

• Founded in:

  1993-03-11

• Address:

  No. 1, Lutai Avenue, Zibo High-tech Zone

• Tax NO.:

  9137030361328152XT

• Registered Funds:

  84.93 million yuan

• Website:

  Log in to view

• Email:

  Log in to view